Capecitabine (Xeloda) is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers by reducing or preventing the progression of cancer cells. In 2017, the global capecitabine market was approximately USD 1,652 Million.
Capecitabine (Xeloda) was launched in 2005 by Roche. The company lost its patent on December 14, 2013. The drug continues to be a solid performer in the market as oral chemotherapy drug for breast and colorectal cancers. The drug saw sales grow over 10% in 2016. Currently, several companies have entered in the market with the generic version of the drug including Emcure Pharmaceuticals Ltd, Genentech, Inc., and many others. Being a potential drug, a number of companies are trying to introduce the new generic products and other synergistic drug used in the of the cancer. For instant, Hikma Pharmaceuticals PLC (Hikma) one of the fast-growing multinational pharmaceutical group, launched Capecitabine Tablets, the generic equivalents to Xeloda Tablets. As per the research, in 2016, U.S. Capecitabine Tablets Market were over USD 472 million.
The report firstly introduced the global capecitabine including application and industry chain overview; Then we deeply analyzed global market on the basis of segmental and regional segmentation.
The report will also include detailed pipeline analysis, recent market scenario, and cost effective analysis of the Capecitabine Vs other available drugs. In the end, the report introduced Capecitabine market competitive share analysis, company profiles and analyst conclusion for the market. The report includes depth research study on the global Capecitabine Market. We are thankful for the support and assistance from the market technical and marketing experts during research team survey.